

SUPPLEMENTARY FIGURES




Supplementary Figure 1. The expression of 14 miRNAs in ccRCC tissues and normal kidney tissues. (A) hsa-miR-126-5p. (B) hsa-miR-185-3p. (C) hsa-miR-188-3p. (D) hsa-miR-210-5p. (E) hsa-miR-222-5p. (F) hsa-miR-486-3p. (G) hsa-miR-486-5p. (H) hsa-miR-500a-3p. (I) hsa-miR-509-3p. (J) hsa-miR-532-5p. (K) hsa-miR-584-5p. (L) hsa-miR-618. (M) hsa-miR-3613-5p. (N) hsa-miR-4772-3p. KIRC: kidney renal clear cell carcinoma.


Α




В



Supplementary Figure 2. Enrichment of the GO terms and KEGG pathways of 201 differentially expressed target mRNAs. (A). Biological process and Cell Components. (B). Molecular Function and KEGG Pathways. GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes.



Supplementary Figure 3. The expression level and survival analysis of six hub genes in ccRCC tissues and normal kidney tissues. (A) The expression level of TRIM2 between KIRC and normal samples. (B) The survival analysis of TRIM2 in TCGA KIRC patients. (C) The expression level of XAF1 between KIRC and normal samples. (D) The survival analysis of XAF1 in TCGA KIRC patients. (E) The expression level of GBP1 between KIRC and normal samples. (F) The survival analysis of GBP1 in TCGA KIRC patients. (G) The expression level of GBP5 between KIRC and normal samples. (H) The survival analysis of GBP5 in TCGA KIRC patients. (I) The expression level of LY6E between KIRC and normal samples. (J) The survival analysis of LY6E in TCGA KIRC patients. (K) The expression level of OAS2 between KIRC and normal samples. (L) The survival analysis of OAS2 in TCGA KIRC patients. TCGA: the cancer genome atlas; KIRC: kidney renal clear cell carcinoma.



Supplementary Figure 4. Potential KEGG pathways TRIM2 was involved in. (A) UBIQUITIN MEDIATED PROTEOLYSIS. (B) TIGHT JUNCTION. (C) CYTOKINE-CYTOKINE RECEPTORINTERACTION. (D) CELL ADHESION MOLECULES. (E) Th1 AND Th2 DIFFERENTIATION. (F) Th17 CELL DIFFERENTIATION. KEGG: Kyoto Encyclopedia of Genes and Genomes.

Drug sensibility Salubrinal negative 3 GNP-2 positive **Paclitaxel** Pyrimethamine GW843682X -log10 (pValue) Bortezomib PHA-665752 Pvalue = 0.05 0 2 3 -5 -<u>2</u> 5 -3 -1 0 4 6

Supplementary Figure 5. Correlation between the expression status of TRIM2 and drug sensitivity of ccRCC cell lines.

Cor